Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
People are getting their news from AI – and it’s altering their views - 223 Most Amusing Messages At any point Sent Among Kids and Their Folks
- 3Cyber Monday 2025: Save over 70% on HBO Max with this Prime Video streaming deal
- 4NASA's Perseverance Mars rover could break the record for miles driven on another planet
- 5The most effective method to Keep up with Proficient Handshakes in a Computerized World
- Don’t let food poisoning crash your Thanksgiving dinner
- Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there
- Why screening for the deadliest cancer in the U.S. misses most cases
- Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
- Putin critic gets six years in penal colony, vows hunger strike
- In the background: Visiting Notable Film Areas All over the Planet
- The Best 10 Innovation Advancements of the Year
- Doctor's orders? ‘Belly laugh at least two to five days a week'
- Dominating the Mastercard Endorsement Cycle: Six Fundamental Stages
